Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
Terminated
Eastern Virginia Medical School
Phase 2
2017-01-01
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to
evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects
with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth
University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential
subjects will be identified in each site's CF clinic.
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
Terminated
Virginia Commonwealth University
Phase 2
2017-01-01
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to
evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects
with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth
University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential
subjects will be identified in each site's CF clinic.
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
2019-07-09
This is a Phase I, open-label, non-randomized, single center study in 48 healthy adult male
and female subjects, aged 18 to 45 years. This study is aimed to investigate the safety and
pharmacokinetics of ceftazidime-avibactam (AVYCAZ) combined with aztreonam (ATM), AVYCAZ
alone, and ATM alone. The study will have 6 arms, arms 1-4 are the single drug administration
treatment groups and will include AVYCAZ per label dosing, AVYCAZ as a continuous infusion
(CI), ATM per label dosing, and ATM as a CI. Arms 5 and 6 are the two AVYCAZ and ATM
combination drug administration treatment groups. The duration of subject participation will
be up to 44 days, and the total length of the study will be 15 months. The primary objective
of this study is to describe the safety of two dosing regimens of AVYCAZ combined with ATM
relative to AVYCAZ alone, and ATM alone in healthy adult subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
